Business Wire23d
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and ...
The data highlighted positive preclinical outcomes with the Company’s glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist KROS101 in melanoma and glioblastoma as well as its ...
BioWorld1mon
Kairos presents next-generation GITR agonist
Glucocorticoid-induced tumor necrosis factor receptor (GITR) and its ligand, GITRL, are involved in immune response regulation. GITR is mainly expressed in activated T cells while GITRL is primarily ...